A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-3394

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children ; day:13 ; month:2 ; year:2020 ; pages:1-17
Health care analysis ; (13.2.2020), 1-17

Creator: Murano, Maria Cristina

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10728-020-00390-1

URN: urn:nbn:de:101:1-2020051120471361170907

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Murano, Maria Cristina
SpringerLink (Online service)

Other Objects (12)

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Abschnitt

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Cultures in bioethics

Problems of bioethics

Zeitschrift

Asian bioethics review

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Abschnitt

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Cultures in bioethics

Problems of bioethics

Zeitschrift

Asian bioethics review

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Abschnitt

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Graffiti | Streetart

FDA

Cultures in bioethics

Problems of bioethics

Zeitschrift

Asian bioethics review

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

FDA

FDA

FDA

FDA

Cultures in bioethics

Problems of bioethics

Asian bioethics review

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

FDA

FDA

FDA

FDA

Cultures in bioethics

Problems of bioethics

Asian bioethics review

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Stature

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations

FDA

FDA

FDA

FDA

Cultures in bioethics

Problems of bioethics

Asian bioethics review

Related objects

Reset password